29 results on '"Maurici, Daniela"'
Search Results
2. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
- Author
-
Kirkland, David, Pfuhler, Stefan, Tweats, David, Aardema, Marilyn, Corvi, Raffaella, Darroudi, Firouz, Elhajouji, Azeddine, Glatt, Hansruedi, Hastwell, Paul, Hayashi, Makoto, Kasper, Peter, Kirchner, Stephan, Lynch, Anthony, Marzin, Daniel, Maurici, Daniela, Meunier, Jean-Roc, Müller, Lutz, Nohynek, Gerhard, Parry, James, Parry, Elizabeth, Thybaud, Veronique, Tice, Ray, van Benthem, Jan, Vanparys, Philippe, and White, Paul
- Published
- 2007
- Full Text
- View/download PDF
3. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay
- Author
-
Maurici, Daniela, Monti, Paola, Campomenosi, Paola, North, Sophie, Frebourg, Thierry, Fronza, Gilberto, and Hainaut, Pierre
- Published
- 2001
- Full Text
- View/download PDF
4. The expression of P-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells
- Author
-
Scotlandi, Katia, Manara, Maria Cristina, Serra, Massimo, Benini, Stefania, Maurici, Daniela, Caputo, Antonella, De Giovanni, Carla, Lollini, Pier-Luigi, Nanni, Patrizia, Picci, Piero, Campanacci, Mario, and Baldini, Nicola
- Published
- 1999
- Full Text
- View/download PDF
5. ECVAM retrospective validation of in vitro micronucleus test (MNT)
- Author
-
Corvi, Raffaella, Albertini, Silvio, Hartung, Thomas, Hoffmann, Sebastian, Maurici, Daniela, Pfuhler, Stefan, van Benthem, Jan, and Vanparys, Philippe
- Published
- 2008
6. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities
- Author
-
Serra, Massimo, Scotlandi, Katia, Manara, Maria Cristina, Maurici, Daniela, Benini, Stefania, Sarti, Manuela, Nini, Giuseppe, Barbanti-Brodano, Giovanni, and Baldini, Nicola
- Published
- 1996
- Full Text
- View/download PDF
7. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma
- Author
-
Baldini, Nicola, Scotlandi, Katia, Serra, Massimo, Kusuzaki, Katsuyuki, Shikita, Toshiharu, Manara, Maria C., Maurici, Daniela, and Campanacci, Mario
- Published
- 1992
- Full Text
- View/download PDF
8. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
- Author
-
Baldini, Nicola, Scotlandi, Katia, Barbanti-Brodano, Giovanni, Manara, Maria Cristina, Maurici, Daniela, Bacci, Gaetano, Bertoni, Franco, Picci, Piero, Sottili, Sandra, Campanacci, Mario, and Serra, Massimo
- Subjects
Osteosarcoma -- Prognosis ,Glycoproteins -- Physiological aspects - Abstract
High levels of P-glycoprotein in tumor cells of osteosarcoma appear to increase the risk of tumor relapse or death following surgery and chemotherapy. Osteosarcoma is a bone tumor that is often cancerous. Researchers studied the levels of the membrane pump P-glycoprotein in tumor cells of 92 patients with osteosarcoma who had surgery and chemotherapy. In 28 (30%) of the tumors, P-glycoprotein appeared at elevated levels in cells throughout the tumor. Tumors located at the end of bones closer to the torso tended to have higher P-glycoprotein levels. During a minimum follow-up of 63 months, the rate of tumor relapse or death during remission was 3.4 times higher in people with high P-glycoprotein levels. Poor response to chemotherapy also appeared to increase the likelihood of a poor outcome.
- Published
- 1995
9. Editorial: Exploring the need to include microbiomes into EFSA's scientific assessments.
- Author
-
Merten, Caroline, Schoonjans, Reinhilde, Di Gioia, Diana, Peláez, Carmen, Sanz, Yolanda, Maurici, Daniela, and Robinson, Tobin
- Abstract
The communities of microorganisms and their genomes in a defined environment are collectively referred to as microbiomes (Marchesi and Ravel, 2015). They include representatives from the Bacteria, Archaea, lower and higher Eukarya, and viruses, and are found in most environments such as soils, aquatic habitats, surfaces and specific lumen of plants, animals and humans. According to ongoing studies, microbiome structures and dynamics across the food system can have both direct and indirect effects on human and animal health, in addition to their impact on food quality, safety and sustainability (CNBBSV concept paper, 2019). Moreover, recent research projects have offered new insights into the associations between microbiomes and a wide range of human diseases as well as their possible impact in modulating the exposure to environmental chemicals. As one of the core tasks of EFSA is to assess risks to human and animal health and/or the environment from substances linked to food and feed production, the increasing understanding of the role of microbiomes in health calls for a prospective mapping of their roles into regulatory scientific assessment processes with a view to understanding their potential health impact. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. EFSA cross‐cutting guidance lifecycle.
- Author
-
European Food Safety Authority (EFSA), Maurici, Daniela, Garcia Matas, Raquel, and Gervelmeyer, Andrea
- Abstract
This document describes the lifecycle of cross‐cutting guidance documents in EFSA. Cross‐cutting guidance documents deal with matters of a horizontal nature in fields that affect scientific areas covered by more than one Panel. The main objective of developing cross‐cutting guidance documents is to harmonise food and feed safety risk assessment in EFSA. The document outlines the procedures for the identification of needs for cross‐cutting guidance documents, their development, implementation, their review and revision. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Genotoxicity testing approaches for the safety assessment of substances used in food contact materials prior to their authorization in the European Union.
- Author
-
Bolognesi, Claudia, Castoldi, Anna F., Crebelli, Riccardo, Barthélémy, Eric, Maurici, Daniela, Wölfle, Detlef, Volk, Katharina, and Castle, Laurence
- Subjects
GENETIC toxicology ,RISK assessment ,MUTAGENICITY testing - Abstract
Food contact materials are all materials and articles intended to come directly or indirectly into contact with food. Before being included in the positive European 'Union list' of authorized substances (monomers, other starting substances and additives) for plastic food contact materials, the European Food Safety Authority (EFSA) must assess their safety 'in use'. If relevant for risk, the safety of the main impurities, reaction and degradation products originating from the manufacturing process is also evaluated. Information on genotoxicity is always required irrespective of the extent of migration and the resulting human exposure, in view of the theoretical lack of threshold for genotoxic events. The 2008 EFSA approach, requiring the testing of food contact materials in three in vitro mutagenicity tests, though still acceptable, is now superseded by the 2011 EFSA Scientific Committee's recommendation for only two complementary tests including a bacterial gene mutation test and an in vitro micronucleus test, to detect two main genetic endpoints (i.e., gene mutations and chromosome aberrations). Follow-up of in vitro positive results depends on the type of genetic effect and on the substance's systemic availability. In this study, we provide an analysis of the data on genotoxicity testing gathered by EFSA on food contact materials for the period 1992-2015. We also illustrate practical examples of the approaches that EFSA took when evaluating 'non standard' food contact chemicals (e.g., polymeric additives, oligomer or other reaction mixtures, and nanosubstances). Additionally, EFSA's experience gained from using non testing methods and/or future possibilities in this area are discussed. Environ. Mol. Mutagen. 58:361-374, 2017. © 2017 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Modulation of different stress pathways after styrene and styrene-7,8-oxide exposure in HepG2 cell line and normal human hepatocytes.
- Author
-
Diodovich, Cristina, Urani, Chiara, Maurici, Daniela, Malerba, Ilaria, Melchioretto, Pasquale, Orlandi, Marco, Zoia, Luca, Campi, Valentina, Carfi', Maria, Pellizzer, Cristian, and Gribaldo, Laura
- Subjects
STYRENE ,MONOMERS ,CARCINOGENS ,HEAT shock proteins ,METALLOTHIONEIN ,LIVER cells ,STYRENE oxide - Abstract
Styrene is one of the most important monomers produced worldwide. IARC classified styrene as a possible carcinogen to humans (group 2B). Styrene-7,8-oxide (SO) is the main reactive metabolite of styrene, and it is found to be genotoxic in several in vitro test systems. Styrene and styrene-7,8-oxide (SO) toxicity to HepG2 cells was investigated by evaluating end-points such as heat shock proteins (Hsps), metallothioneins (MT), apoptosis-related proteins, accumulation of styrene within the cells and expression of two isoforms of cytochrome P450. The potential activity of styrene and styrene-7,8-oxide in modulating gene expression was also investigated. The results showed induction of Hsp70, metallothioneins, BclX
S/L and c-myc expression and a decrease in Bax expression in HepG2 after treatments, confirming that these compounds activated protective mechanisms. Moreover, up-regulation of TGF β2 and TGF βRIII in HepG2 cells was found after exposure to styrene, while in human primary hepatocytes these genes were down-regulated after both treatments. Finally, it was found that styrene and SO treatments did not induce CYP1A2 and CYP2E1 protein expression. In conclusion, both compounds caused toxic stress in HepG2 cells, with SO being more toxic; in the meantime, a different effect of the two compounds in HepG2 cells and primary human hepatocytes was observed regarding their activity in gene modulation. Copyright © 2006 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2006
- Full Text
- View/download PDF
13. The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy.
- Author
-
Seemann, Séverine, Maurici, Daniela, Olivier, Magali, Fromentel, Claude Caron, and Hainaut, Pierre
- Subjects
- *
TUMOR suppressor genes , *P53 protein , *TRANSCRIPTION factors , *CANCER genetics , *CANCER cells , *CANCER vaccines - Abstract
The p53 protein is an inducible transcription factor with multiple anti-proliferative roles in response to genotoxic damage; unprogrammed proliferative stimuli; and deprivation of oxygen, nutrients, or ribonucleotides. Inactivation of the TP53 gene by mutation or deletion is the most common event in human cancer. Loss of p53 function compromises genetic homeostasis in cells exposed to mutagens and prevents normal cytotoxic responses to cancer therapies. Genetic and pharmacological approaches are being developed with the ultimate goal of restoring or controlling p53 functions in cancer patients.Genetic interventions aiming at expressing wild-type TP53 in cancer cells, either by retroviral or adenoviral transfer, have met limited clinical success. However, recently, the use of a defective adenovirus (ONYX-015) that selectively kills p53-incompetent cells has shown promising effects in pre-clinical and clinical studies. Pharmacological methods are under development to either stimulate wild-type p53 protein function or induce p53 mutant proteins to resume wild-type functions. These methods are based on small chemicals (CP-31388, PRIMA-1), peptides (CDB3), or single-chain Fv antibody fragments corresponding to defined p53 domains. In addition, detection of mutant TP53 may also serve as a marker for early cancer detection, prediction, and prognosis. In this review, we discuss the mechanisms underlying these approaches and their perspectives for cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
14. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.
- Author
-
North, Sophie, Pluquet, Olivier, Maurici, Daniela, El Ghissassi, Fatiha, and Hainaut, Pierre
- Published
- 2002
- Full Text
- View/download PDF
15. Cytologic and fluorescence in situ hybridization (FISH) examination of metanephric adenoma.
- Author
-
Renshaw, Andrew A., Maurici, Daniela, and Fletcher, Jonathan A.
- Published
- 1997
- Full Text
- View/download PDF
16. Clinical relevance of Ki-67 expression in bone tumors.
- Author
-
Scotlandi, Katia, Serra, Massimo, Manara, M. Cristina, Maurici, Daniela, Benini, Stefania, Nini, Giuseppe, Campanacci, Mario, Baldini, Nicola, Scotlandi, K, Serra, M, Manara, M C, Maurici, D, Benini, S, Nini, G, Campanacci, M, and Baldini, N
- Published
- 1995
- Full Text
- View/download PDF
17. Adriamycin binding assay: a valuable chemosensitivity test in human osteosarcoma.
- Author
-
Baldini, Nicola, Scotlandi, Katia, Serra, Massimo, Kusuzaki, Katsuyuki, Shikita, Toshiharu, Manara, Maria, Maurici, Daniela, and Campanacci, Mario
- Abstract
The reliability of a simple method evaluating the pattern of subcellular binding of Adriamycin (Adriamycin binding assay, ABA) as an index of sensitivity was demonstrated in different primary cultures and in sensitive and resistant cell lines of human osteosarcoma. After exposure to Adriamycin (10 μg/ml for 30 min at 37°C), living sensitive cells showed selective intranuclear uptake of the drug, whereas in resistant cells no distinct subcellular distribution was observed. The binding pattern of Adriamycin in sensitive and in highly resistant cells was inversely related to the expression of P-glycoprotein. However, low levels of resistance in vitro, not detectable by increased levels of expression of P-glycoprotein, were revealed by ABA. The use of ABA in combination with the estimate of P-glycoprotein expression is recommended in clinical practice as an accurate means for predicting the sensitivity of osteosarcoma to Adriamycin. [ABSTRACT FROM AUTHOR]
- Published
- 1993
- Full Text
- View/download PDF
18. Pre-Treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin.
- Author
-
Scotlandi, Katia, Serra, Massimo, Manara, Maria Cristina, Lollini, Pier-Luigi, Maurici, Daniela, Bufalo, Donatella Del, and Baldini, Nicola
- Published
- 1994
- Full Text
- View/download PDF
19. Outcome of the public consultation on the draft statement on genotoxicity assessment of chemical mixtures.
- Author
-
Carfì, Maria, Manini, Paola, Martino, Carla, Maurici, Daniela, Morte, Juan Parra, Rossi, Annamaria, Vettori, Maria Vittoria, and Schlatter, Josef
- Subjects
SCIENTIFIC community - Abstract
The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the genotoxicity assessment of chemical mixtures. The draft statement was prepared by a dedicated working group of the Scientific Committee and endorsed by the Scientific Committee for public consultation at its 89th plenary meeting of 28‐29 May 2018. The public consultation for this document was open from 26 June until 9 September 2018. EFSA received 73 comments from 16 interested parties. EFSA's Scientific Committee wishes to thank all stakeholders for their contributions. This report presents statistics on the comments received and provides a summarised description of how the comments were addressed in the finalisation of the document. The stakeholders valuable and detailed comments were taken into account by the Scientific Committee to prepare an updated version of the statement on genotoxicity assessment of mixtures. The statement was discussed and adopted at the Scientific Committee plenary meeting on 22 November 2018, and is published in the EFSA Journal. This publication is linked to the following EFSA Journal article: http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2019.5519/full [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Guidance on aneugenicity assessment.
- Author
-
More SJ, Bampidis V, Bragard C, Halldorsson TI, Hernández-Jerez AF, Hougaard Bennekou S, Koutsoumanis K, Lambré C, Machera K, Naegeli H, Nielsen SS, Schlatter J, Schrenk D, Turck D, Younes M, Aquilina G, Bignami M, Bolognesi C, Crebelli R, Gürtler R, Marcon F, Nielsen E, Vleminckx C, Carfì M, Martino C, Maurici D, Parra Morte J, Rossi A, and Benford D
- Abstract
The EFSA Scientific Committee was asked to provide guidance on the most appropriate in vivo tests to follow up on positive in vitro results for aneugenicity, and on the approach to risk assessment for substances that are aneugenic but not clastogenic nor causing gene mutations. The Scientific Committee confirmed that the preferred approach is to perform an in vivo mammalian erythrocyte micronucleus test with a relevant route of administration. If this is positive, it demonstrates that the substance is aneugenic in vivo . A negative result with evidence that the bone marrow is exposed to the test substance supports a conclusion that aneugenic activity is not expressed in vivo . If there is no evidence of exposure to the bone marrow, a negative result is viewed as inconclusive and further studies are required. The liver micronucleus assay, even though not yet fully validated, can provide supporting information for substances that are aneugenic following metabolic activation. The gastrointestinal micronucleus test, conversely, to be further developed, may help to assess aneugenic potential at the initial site of contact for substances that are aneugenic in vitro without metabolic activation. Based on the evidence in relation to mechanisms of aneugenicity, the Scientific Committee concluded that, in principle, health-based guidance values can be established for substances that are aneugenic but not clastogenic nor causing gene mutations, provided that a comprehensive toxicological database is available. For situations in which the toxicological database is not sufficient to establish health-based guidance values, some approaches to risk assessment are proposed. The Scientific Committee recommends further development of the gastrointestinal micronucleus test, and research to improve the understanding of aneugenicity to support risk assessment., (© 2021 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)
- Published
- 2021
- Full Text
- View/download PDF
21. Scientific Opinion of the Scientific Panel on Plant Protection Products and their Residues (PPR Panel) on the genotoxic potential of triazine amine (metabolite common to several sulfonylurea active substances).
- Author
-
Hernandez-Jerez AF, Adriaanse P, Aldrich A, Berny P, Coja T, Duquesne S, Gimsing AL, Marinovich M, Millet M, Pelkonen O, Pieper S, Tiktak A, Topping CJ, Tzoulaki I, Widenfalk A, Wolterink G, Benford D, Aquilina G, Bignami M, Bolognesi C, Crebelli R, Guertler R, Marcon F, Nielsen E, Schlatter JR, Vleminckx C, Maurici D, and Parra Morte JM
- Abstract
The Panel received a mandate from the European Commission to assess the genotoxic potential of triazine amine based on available information submitted by the applicants. Available information includes experimental genotoxicity data on triazine amine, Quantitative Structure-Activity Relationship (QSAR) analysis and read across with structurally similar compounds. Based on the overall weight of evidence, the Panel, in agreement with the cross-cutting Working Group Genotoxicity, concluded that there is no concern for the potential of triazine amine to induce gene mutations and clastogenicity; however, the potential to induce aneugenicity was not adequately investigated. For a conclusion, an in vitro micronucleus assay performed with triazine amine would be needed., (© 2020 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)
- Published
- 2020
- Full Text
- View/download PDF
22. Genotoxicity assessment of chemical mixtures.
- Author
-
More S, Bampidis V, Benford D, Boesten J, Bragard C, Halldorsson T, Hernandez-Jerez A, Hougaard-Bennekou S, Koutsoumanis K, Naegeli H, Nielsen SS, Schrenk D, Silano V, Turck D, Younes M, Aquilina G, Crebelli R, Gürtler R, Hirsch-Ernst KI, Mosesso P, Nielsen E, Solecki R, Carfì M, Martino C, Maurici D, Parra Morte J, and Schlatter J
- Abstract
The EFSA Scientific Committee addressed in this document the peculiarities related to the genotoxicity assessment of chemical mixtures. The EFSA Scientific Committee suggests that first a mixture should be chemically characterised as far as possible. Although the characterisation of mixtures is relevant also for other toxicity aspects, it is particularly significant for the assessment of genotoxicity. If a mixture contains one or more chemical substances that are individually assessed to be genotoxic in vivo via a relevant route of administration, the mixture raises concern for genotoxicity. If a fully chemically defined mixture does not contain genotoxic chemical substances, the mixture is of no concern with respect to genotoxicity. If a mixture contains a fraction of chemical substances that have not been chemically identified, experimental testing of the unidentified fraction should be considered as the first option or, if this is not feasible, testing of the whole mixture should be undertaken. If testing of these fraction(s) or of the whole mixture in an adequately performed set of in vitro assays provides clearly negative results, the mixture does not raise concern for genotoxicity. If in vitro testing provides one or more positive results, an in vivo follow-up study should be considered. For negative results in the in vivo follow-up test(s), the possible limitations of in vivo testing should be weighed in an uncertainty analysis before reaching a conclusion of no concern with respect to genotoxicity. For positive results in the in vivo follow-up test(s), it can be concluded that the mixture does raise a concern about genotoxicity., (© 2019 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)
- Published
- 2018
- Full Text
- View/download PDF
23. Clarification of some aspects related to genotoxicity assessment.
- Author
-
Hardy A, Benford D, Halldorsson T, Jeger M, Knutsen HK, More S, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Younes M, Aquilina G, Crebelli R, Gürtler R, Hirsch-Ernst KI, Mosesso P, Nielsen E, van Benthem J, Carfì M, Georgiadis N, Maurici D, Parra Morte J, and Schlatter J
- Abstract
The European Commission requested EFSA to provide advice on the following: (1) the suitability of the unscheduled DNA synthesis (UDS) in vivo assay to follow-up positive results in in vitro gene mutation tests; (2) the adequacy to demonstrate target tissue exposure in in vivo studies, particularly in the mammalian erythrocyte micronucleus test; (3) the use of data in a weight-of-evidence approach to conclude on the genotoxic potential of substances and the consequent setting of health-based guidance values. The Scientific Committee concluded that the first question should be addressed in both a retrospective and a prospective way: for future assessments, it is recommended no longer performing the UDS test. For re-assessments, if the outcome of the UDS is negative, the reliability and significance of results should be carefully evaluated in a weight-of-evidence approach, before deciding whether more sensitive tests such as transgenic assay or in vivo comet assay would be needed to complete the assessment. Regarding the second question, the Scientific Committee concluded that it should be addressed in lines of evidence of bone marrow exposure: toxicity to the bone marrow in itself provides sufficient evidence to allow concluding on the validity of a negative outcome of a study. All other lines of evidence of target tissue exposure should be assessed within a weight-of-evidence approach. Regarding the third question, the Scientific Committee concluded that any available data that may assist in reducing the uncertainty in the assessment of the genotoxic potential of a substance should be taken into consideration. If the overall evaluation leaves no concerns for genotoxicity, health-based guidance values may be established. However, if concerns for genotoxicity remain, establishing health-based guidance values is not considered appropriate., (© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)
- Published
- 2017
- Full Text
- View/download PDF
24. Scientific motivations and criteria to consider updating EFSA scientific assessments.
- Author
-
Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S, Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Schlatter JR, Silano V, Solecki R, Turck D, Brock T, Chesson A, Karenlampi S, Lambre C, Sanz Y, Goumperis T, Kleiner J, and Maurici D
- Abstract
EFSA is committed to assess and communicate the risks occurring in the food and feed chain from farm to fork and to provide other forms of scientific advice. This work, carried out by EFSA since its inception, has resulted in the adoption of thousands of scientific assessments. EFSA is obliged to re-assess past assessments in specific regulatory contexts such as those on food and feed additives, active substances in plant protection products and genetically modified food and feed. In other sectors, the consideration for updating past EFSA scientific assessments is taken on an ad hoc basis mainly depending on specific requests by risk managers or on EFSA self-tasking. If safety is potentially at stake in any area within EFSA's remit, the readiness to update past scientific assessments is important to keep EFSA at the forefront of science and to promote an effective risk assessment. Although this task might be very complex and resource demanding, it is fundamental to EFSA's mission. The present EFSA Scientific Committee opinion deals with scientific motivations and criteria to contribute to the timely updating of EFSA scientific assessments. It is recognised that the decision for updating should be agreed following careful consideration of all the relevant elements by the EFSA management, in collaboration with risk managers and stakeholders. The present opinion addresses the scientific approaches through which it would be possible for EFSA to increase the speed and effectiveness of the acquisition of new data, as well as, to improve the consequent evaluations to assess the relevance and reliability of new data in the context of contributing to the better definition of whether to update past scientific assessments., (© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.)
- Published
- 2017
- Full Text
- View/download PDF
25. Genotoxicty and mutagenicity.
- Author
-
Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent C, Loprieno N, Pasanen M, Pfuhler S, Phillips B, Sabbioni E, Sanner T, and Vanparys P
- Subjects
- Animal Testing Alternatives legislation & jurisprudence, Animal Testing Alternatives standards, Animals, Carcinogenicity Tests methods, Carcinogens chemistry, Carcinogens classification, Cells, Cultured, Consumer Product Safety legislation & jurisprudence, Consumer Product Safety standards, Cosmetics chemistry, Cosmetics classification, European Union, Humans, Mutagenicity Tests methods, Mutagens chemistry, Mutagens classification, Structure-Activity Relationship, Carcinogens toxicity, Cosmetics toxicity, Mutagens toxicity
- Published
- 2005
- Full Text
- View/download PDF
26. Carcinogenicity.
- Author
-
Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent C, Loprieno N, Pasanen M, Pfuhler S, Phillips B, Prentice D, Sabbioni E, Sanner T, and Vanparys P
- Subjects
- Animal Testing Alternatives legislation & jurisprudence, Animal Testing Alternatives standards, Animals, Carcinogenicity Tests methods, Carcinogens chemistry, Carcinogens classification, Cell Transformation, Neoplastic drug effects, Cell Transformation, Neoplastic pathology, Cells, Cultured, Consumer Product Safety legislation & jurisprudence, Consumer Product Safety standards, Cosmetics chemistry, Cosmetics classification, European Union, Gap Junctions drug effects, Gap Junctions pathology, Mice, Mice, Transgenic, Quantitative Structure-Activity Relationship, Rats, Carcinogens toxicity, Cosmetics toxicity
- Published
- 2005
- Full Text
- View/download PDF
27. New insights into the mechanisms involved in renal proximal tubular damage induced in vitro by ochratoxin A.
- Author
-
Gennari A, Pazos P, Boveri M, Callaghan R, Casado J, Maurici D, Corsini E, and Prieto P
- Subjects
- Animals, Cell Survival drug effects, Cytoskeleton drug effects, Gene Expression Profiling, Kidney Tubules, Proximal drug effects, LLC-PK1 Cells, Mitochondria drug effects, Oligonucleotide Array Sequence Analysis, Swine, Apoptosis drug effects, Cytoskeleton pathology, Gene Expression Regulation drug effects, Kidney Tubules, Proximal pathology, Mitochondria pathology, Ochratoxins toxicity
- Abstract
The mycotoxin ochratoxin A is a contaminant of human and animal food products. It is a potent nephrotoxin known to damage the proximal tubule. The aim of this work was to investigate the effects of ochratoxin A on a porcine renal proximal tubular epithelial cell line (LLC-PK1), and to identify sensitive endpoints revealing damage at the epithelial barrier level and at the molecular level. Cells exposed for 24 h to 5-10 microM ochratoxin indicated a clear damage to the intactness of the epithelial barrier, as shown by measurements of trans-epithelial resistance and zonula occludens-1 protein expression. At the mitochondrial level we observed alterations of the normal functions, such as an increase of the membrane potential, the formation of straight extensions, and the formation of giant mitochondria. At higher ochratoxin concentrations (50 microM), at which cytotoxicity assays revealed a significant toxicity, alterations of the cytoskeleton organization and induction of apoptosis were evident. In addition, we analyzed the expression of genes by using a cDNA macroarray. Our data indicate that ochratoxin-induced nephrotoxicity can be detected at the barrier and at the mitochondrial level at rather low concentrations, at which conventional cytotoxicity assays are unable to reveal toxic effects., (Copyright 2004 Wiley Periodicals, Inc.)
- Published
- 2004
- Full Text
- View/download PDF
28. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
- Author
-
Fulci G, Ishii N, Maurici D, Gernert KM, Hainaut P, Kaur B, and Van Meir EG
- Subjects
- Adult, Cell Division genetics, Cell Transformation, Neoplastic genetics, Cyclin-Dependent Kinase Inhibitor p21, Cyclins genetics, DNA, Neoplasm genetics, DNA, Neoplasm metabolism, Disease Progression, Gene Expression Regulation, Neoplastic, Humans, Male, Models, Molecular, Neoplasm Recurrence, Local genetics, Proto-Oncogene Proteins genetics, Transcriptional Activation, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, bcl-2-Associated X Protein, Astrocytoma genetics, Brain Neoplasms genetics, Genes, p53 genetics, Germ-Line Mutation, Point Mutation, Precancerous Conditions genetics, Proto-Oncogene Proteins c-bcl-2, Tumor Suppressor Protein p53 physiology
- Abstract
Little is known about the genetic and molecular events leading to the early stages of human astrocytoma formation. To examine this issue, we analyzed the significance of sequential accumulation of two somatic point mutations (R267W and E258D) in the TP53 gene during the initiation of astrocytoma in a patient born with a single germ-line p53 point mutation (R283H). We adapted a p53 transcriptional assay in yeast to establish the temporal occurrence and allelic distribution of the p53 mutations present in the patient and characterized these mutations through functional assays and structural modeling. Our results show that the first somatic mutation occurred at codon 267 on the p53 allele harboring the germ-line mutation R283H, whereas the second somatic mutation occurred in the remaining wild-type (wt) allele at codon 258. These two mutations induced the formation of tumor cells with the genotype p53(267W+283H/258D), which comprised 70% of the cells in the primary WHO grade II astrocytoma. Another 8% of cells within the tumor had the partially mutated genotype p53(267W+283H/WT) and represented the remnants of a clinically undetectable intermediate stage of astrocytic neoplastic transformation. The remaining 22% of cells had the constitutive p53(283H/WT) genotype and likely consisted of nontumor cells. Functional analysis of the p53 alleles present in the patient's tumor indicated that the germ-line p53(R283H) could transactivate the CDKN1A((p21, WAF1, cip1, SDI1)) but not the BAX gene and retained the ability to induce growth arrest of human glioblastoma cells. The p53(R267W+R283H) and p53(E258D) were incapable of transactivating either promoter or inducing growth arrest. Modeling of p53 interaction with DNA suggests that R283H mutation may weaken the sequence-specific interaction of p53 lysine 120 with the BAX gene but not the CDKN1A p53-responsive elements. Taken together, these results have characterized, for the first time, the genetic events defining a clinically undetectable precursor lesion leading to a grade II astrocytoma. They also suggest that astrocytoma initiation in this patient resulted from monoclonal evolution driven by a sequential loss of proapoptotic and growth arrest functions of p53.
- Published
- 2002
29. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.
- Author
-
North S, Pluquet O, Maurici D, El-Ghissassi F, and Hainaut P
- Subjects
- Cell Cycle drug effects, Cyclin-Dependent Kinase Inhibitor p21, Cyclins metabolism, Cytoprotection, Dose-Response Relationship, Drug, Electrophoretic Mobility Shift Assay, Esophageal Neoplasms genetics, Humans, Mutation, Protein Conformation, RNA, Neoplasm biosynthesis, Temperature, Tumor Cells, Cultured, Tumor Suppressor Protein p53 chemistry, Tumor Suppressor Protein p53 genetics, Esophageal Neoplasms metabolism, Genes, p53, Mercaptoethylamines pharmacology, Radiation-Protective Agents pharmacology, Tumor Suppressor Protein p53 metabolism
- Abstract
The aminothiol WR1065, the active metabolite of the cytoprotector amifostine, exerts its antimutagenic effects through free-radical scavenging and other unknown mechanisms. In an earlier report, we showed that WR1065 activates wild-type p53 in MCF-7 cells, leading to p53-dependent arrest in the G(1) phase of the cell cycle. To determine whether WR1065 activates p53 by modulating protein conformation, we analyzed its effects on p53 conformation and activity in the esophageal cancer cell line TE-1. This cell line contains a mutation in codon 272 of p53 (p53(V272M), with methionine instead of a valine), conferring temperature-sensitive properties to the p53 protein. At the nonpermissive temperature (37 degrees C), p53(V272M) adopts the mutant p53 conformation (nonreactive with the antibody PAb1620), does not bind specifically to DNA, and is not activated in response to DNA-damaging treatment. However, treatment with 0.5-4 mM WR1065 partially restored wild-type conformation at 37 degrees C, stimulated DNA binding activity, and increased the expression of p53 target genes WAF-1, GADD45, and MDM2, leading to cell-cycle arrest in G(1). These results suggest that WR1065 activates p53 through a mechanism distinct from DNA-damage signaling, which involves modulation of p53 protein conformation., (Copyright 2002 Wiley-Liss, Inc.)
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.